Abstract
The clinical course of multiple sclerosis (MS) is heterogeneous, varying between patients as well as over time. Classification criteria define the relapsing and progressive forms of MS as well as active and stable disease. Prior to the advent of disease-modifying therapies (DMTs), the majority of patients developed a secondarily progressive course. Randomized clinical trials, long-term extension trials, and observational trials provide data on the impact of DMTs on relapses and progression; however, use of these currently available studies to assess the effect on MS disease course is limited by duration or selection bias. Further analysis of a large populations of MS patients is needed to ascertain the long-term effects of DMTs on MS clinical course.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Translational Neuroimmunology in Multiple Sclerosis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
